聚乙二醇化重组人粒细胞集落刺激因子联合生血宝合剂预防恶性肿瘤化疗后骨髓抑制的临床观察

Clinical observation on prophylactic therapy of polyglycol recombinant human granulocyte colony-stimulating factor combined with Shengxuebao Mixture for bone marrow suppression after chemotherapy in malignant tumors

目的评价聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)联合生血宝合剂预防恶性肿瘤化疗后骨髓抑制的有效性和安全性。方法将前一次化疗周期接受化疗后发生Ⅳ度骨髓抑制的61例恶性肿瘤患者,分为观察组31例与对照组30例。观察组本次化疗周期后48 h给予皮下注射PEG-rhG-CSF联合生血宝合剂口服治疗,对照组本次化疗周期后48 h给予PEG-rhG-CSF皮下注射治疗。比较两组治疗后白细胞及中性粒细胞的变化情况,评价两组骨髓抑制程度,比较两组不良反应发生情况。结果治疗后,两组的白细胞、中性粒细胞差异无统计学意义(P>0.05),但观察组骨髓抑制发生率低于对照组(P<0.05)。两组骨痛、注射部位疼痛、乏力发生率差异无统计学意义(P>0.05)。结论PEG-rhG-CSF联合生血宝合剂可以降低恶性肿瘤化疗后骨髓抑制的发生率,且安全性良好。

Objective To evaluate the effectiveness and safety of prophylactic therapy of polyglycol recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF)combined with Shengxuebao Mixture for bone marrow suppression after chemotherapy in malignant tumors.Methods Sixty-one patients with malignant tumors who developed gradeⅣbone marrow suppression after the last cycle of chemotherapy were enrolled and divided into 31 cases in the observation group and 30 cases in the control group.The observation group was given subcutaneous injection of PEG-rhG-CSF in combination with oral Shengxuebao Mixture 48 hours after the chemotherapy cycle,whereas the control group was given subcutaneous injection of PEG-rhG-CSF 48 hours after the chemotherapy cycle.Changes in WBC and neutrophil after treatment were compared between the two groups,the degree of bone marrow suppression was assessed in both groups,and the incidence of adverse reactions were compared between the two groups.Results There was no statistically significant difference in WBC or neutrophil between the two groups(P<0.05),but the incidence rate in the observation group was lower than that in the control group(P<0.05).There were no statistical significant differences between the two groups in incidence rate of bone pain,injection site pain or fatigue(P>0.05).Conclusion PEG-rhG-CSF combined with Shengxuebao Mixture can reduce the incidence rate of bone marrow suppression in malignant tumors after chemotherapy,and has good safety.